726 related articles for article (PubMed ID: 33754187)
1. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Saad F; Chi KN; Shore ND; Graff JN; Posadas EM; Lattouf JB; Espina BM; Zhu E; Yu A; Hazra A; De Meulder M; Mamidi RNVS; Bradic B; Francis P; Hayreh V; Rezazadeh Kalebasty A
Cancer Chemother Pharmacol; 2021 Jul; 88(1):25-37. PubMed ID: 33754187
[TBL] [Abstract][Full Text] [Related]
2. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
3. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
[TBL] [Abstract][Full Text] [Related]
5. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
[TBL] [Abstract][Full Text] [Related]
6. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira de Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S;
J Clin Oncol; 2023 Jun; 41(18):3339-3351. PubMed ID: 36952634
[TBL] [Abstract][Full Text] [Related]
7. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Chi KN; Sandhu S; Smith MR; Attard G; Saad M; Olmos D; Castro E; Roubaud G; Pereira de Santana Gomes AJ; Small EJ; Rathkopf DE; Gurney H; Jung W; Mason GE; Dibaj S; Wu D; Diorio B; Urtishak K; Del Corral A; Francis P; Kim W; Efstathiou E
Ann Oncol; 2023 Sep; 34(9):772-782. PubMed ID: 37399894
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
[TBL] [Abstract][Full Text] [Related]
9. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
10. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract][Full Text] [Related]
11. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Rathkopf DE; Antonarakis ES; Shore ND; Tutrone RF; Alumkal JJ; Ryan CJ; Saleh M; Hauke RJ; Bandekar R; Maneval EC; de Boer CJ; Yu MK; Scher HI
Clin Cancer Res; 2017 Jul; 23(14):3544-3551. PubMed ID: 28213364
[No Abstract] [Full Text] [Related]
12. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
[TBL] [Abstract][Full Text] [Related]
13. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR; Scher HI; Sandhu S; Efstathiou E; Lara PN; Yu EY; George DJ; Chi KN; Saad F; Ståhl O; Olmos D; Danila DC; Mason GE; Espina BM; Zhao X; Urtishak KA; Francis P; Lopez-Gitlitz A; Fizazi K;
Lancet Oncol; 2022 Mar; 23(3):362-373. PubMed ID: 35131040
[TBL] [Abstract][Full Text] [Related]
14. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Yonemori K; Shimizu T; Kondo S; Iwasa S; Koyama T; Kitano S; Sato J; Shimomura A; Shibaki R; Suri A; Kase Y; Sumino S; Tamura K; Yamamoto N
Jpn J Clin Oncol; 2021 Apr; 51(5):693-699. PubMed ID: 33621324
[TBL] [Abstract][Full Text] [Related]
15. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
16. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
17. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
18. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
19. Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Chi KN; Fleshner N; Chiuri VE; Van Bruwaene S; Hafron J; McNeel DG; De Porre P; Maul RS; Daksh M; Zhong X; Mason GE; Tutrone RF
Oncologist; 2023 May; 28(5):e309-e312. PubMed ID: 36994854
[TBL] [Abstract][Full Text] [Related]
20. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]